Literature DB >> 22789497

Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projects.

Ekaterina V Kurbatova1, Allison Taylor, Victoria M Gammino, Jaime Bayona, Mercedes Becerra, Manfred Danilovitz, Dennis Falzon, Irina Gelmanova, Salmaan Keshavjee, Vaira Leimane, Carole D Mitnick, Ma Imelda Quelapio, Vija Riekstina, Piret Viiklepp, Matteo Zignol, J Peter Cegielski.   

Abstract

The Objective of this analysis was to identify predictors of death, failure, and default among MDR-TB patients treated with second-line drugs in DOTS-plus projects in Estonia, Latvia, Philippines, Russia, and Peru, 2000-2004. Risk ratios (RR) with 95% confidence intervals (CI) were calculated using multivariable regression. Of 1768 patients, treatment outcomes were: cure/completed - 1156 (65%), died - 200 (11%), default - 241 (14%), failure - 118 (7%). Independent predictors of death included: age>45 years (RR = 1.90 (95%CI 1.29-2.80), HIV infection (RR = 4.22 (2.65-6.72)), extrapulmonary disease (RR = 1.54 (1.04-2.26)), BMI<18.5 (RR = 2.71 (1.91-3.85)), previous use of fluoroquinolones (RR = 1.91 (1.31-2.78)), resistance to any thioamide (RR = 1.59 (1.14-2.22)), baseline positive smear (RR = 2.22 (1.60-3.10)), no culture conversion by 3rd month of treatment (RR = 1.69 (1.19-2.41)); failure: cavitary disease (RR = 1.73 (1.07-2.80)), resistance to any fluoroquinolone (RR = 2.73 (1.71-4.37)) and any thioamide (RR = 1.62 (1.12-2.34)), and no culture conversion by 3rd month (RR = 5.84 (3.02-11.27)); default: unemployment (RR = 1.50 (1.12-2.01)), homelessness (RR = 1.52 (1.00-2.31)), imprisonment (RR = 1.86 (1.42-2.45)), alcohol abuse (RR = 1.60 (1.18-2.16)), and baseline positive smear (RR = 1.35 (1.07-1.71)). Patients with biomedical risk factors for treatment failure or death should receive heightened medical attention. To prevent treatment default, management of patients who are unemployed, homeless, alcoholic, or have a prison history requires extra measures to insure treatment completion. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22789497      PMCID: PMC4749016          DOI: 10.1016/j.tube.2012.06.003

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  13 in total

1.  Bacteriologic monitoring of multidrug-resistant tuberculosis patients in five DOTS-Plus pilot projects.

Authors:  V M Gammino; A B Taylor; M L Rich; J Bayona; M C Becerra; C Bonilla; I Gelmanova; V Hollo; E Jaramillo; S Keshavjee; V Leimane; C D Mitnick; M I D Quelapio; V Riektsina; T E Tupasi; C D Wells; M Zignol; P J Cegielski
Journal:  Int J Tuberc Lung Dis       Date:  2011-10       Impact factor: 2.373

2.  Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative.

Authors:  E Nathanson; R Gupta; P Huamani; V Leimane; A D Pasechnikov; T E Tupasi; K Vink; E Jaramillo; M A Espinal
Journal:  Int J Tuberc Lung Dis       Date:  2004-11       Impact factor: 2.373

3.  Adverse reactions among patients being treated for MDR-TB in Tomsk, Russia.

Authors:  S S Shin; A D Pasechnikov; I Y Gelmanova; G G Peremitin; A K Strelis; S Mishustin; A Barnashov; Y Karpeichik; Y G Andreev; V T Golubchikova; T P Tonkel; G V Yanova; A Yedilbayev; M L Rich; J S Mukherjee; J J Furin; S Atwood; P E Farmer; S Keshavjee
Journal:  Int J Tuberc Lung Dis       Date:  2007-12       Impact factor: 2.373

4.  Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis?

Authors:  G B Migliori; C Lange; E Girardi; R Centis; G Besozzi; K Kliiman; L R Codecasa; A Spanevello; D M Cirillo
Journal:  Eur Respir J       Date:  2008-04       Impact factor: 16.671

5.  Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000-2004.

Authors:  E Bloss; L Kuksa; T H Holtz; V Riekstina; V Skripconoka; S Kammerer; V Leimane
Journal:  Int J Tuberc Lung Dis       Date:  2010-03       Impact factor: 2.373

6.  Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome.

Authors:  Timothy H Holtz; Maya Sternberg; Steve Kammerer; Kayla F Laserson; Vija Riekstina; Evija Zarovska; Vija Skripconoka; Charles D Wells; Vaira Leimane
Journal:  Ann Intern Med       Date:  2006-05-02       Impact factor: 25.391

7.  Social support and incentives programme for patients with tuberculosis: experience from the Russian Federation.

Authors:  W M Jakubowiak; E M Bogorodskaya; S E Borisov; I D Danilova; O B Lomakina; E V Kourbatova
Journal:  Int J Tuberc Lung Dis       Date:  2007-11       Impact factor: 2.373

Review 8.  Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis.

Authors:  Evan W Orenstein; Sanjay Basu; N Sarita Shah; Jason R Andrews; Gerald H Friedland; Anthony P Moll; Neel R Gandhi; Alison P Galvani
Journal:  Lancet Infect Dis       Date:  2009-03       Impact factor: 25.071

Review 9.  Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis.

Authors:  James C Johnston; Neal C Shahidi; Mohsen Sadatsafavi; J Mark Fitzgerald
Journal:  PLoS One       Date:  2009-09-09       Impact factor: 3.240

10.  Multidrug-resistant tuberculosis management in resource-limited settings.

Authors:  Eva Nathanson; Catharina Lambregts-van Weezenbeek; Michael L Rich; Rajesh Gupta; Jaime Bayona; Kai Blöndal; José A Caminero; J Peter Cegielski; Manfred Danilovits; Marcos A Espinal; Vahur Hollo; Ernesto Jaramillo; Vaira Leimane; Carole D Mitnick; Joia S Mukherjee; Paul Nunn; Alexander Pasechnikov; Thelma Tupasi; Charles Wells; Mario C Raviglione
Journal:  Emerg Infect Dis       Date:  2006-09       Impact factor: 6.883

View more
  64 in total

1.  Simultaneous analysis of 11 medications for drug resistant TB in small hair samples to quantify adherence and exposure using a validated LC-MS/MS panel.

Authors:  Roy Gerona; Anita Wen; David Aguilar; Jamie Shum; Andrew Reckers; Peter Bacchetti; Monica Gandhi; John Metcalfe
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2019-07-23       Impact factor: 3.205

2.  Predictors of unfavourable treatment outcome in patients with multidrug-resistant tuberculosis in India.

Authors:  D Nair; B Velayutham; T Kannan; J P Tripathy; A D Harries; M Natrajan; S Swaminathan
Journal:  Public Health Action       Date:  2017-03-21

3.  Incorporation of Social Determinants of Health in the Peer-Reviewed Literature: A Systematic Review of Articles Authored by the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention.

Authors:  Eleanor E Friedman; Hazel D Dean; Wayne A Duffus
Journal:  Public Health Rep       Date:  2018-06-06       Impact factor: 2.792

4.  The impact of alcohol use on tuberculosis treatment outcomes: a systematic review and meta-analysis.

Authors:  E J Ragan; M B Kleinman; B Sweigart; N Gnatienko; C D Parry; C R Horsburgh; M P LaValley; B Myers; K R Jacobson
Journal:  Int J Tuberc Lung Dis       Date:  2020-01-01       Impact factor: 2.373

5.  Surveillance or support: The experience of direct observation during tuberculosis treatment.

Authors:  Ietza Bojorquez; Irais Salazar; Richard S Garfein; Paris Cerecer; Timothy C Rodwell
Journal:  Glob Public Health       Date:  2016-10-16

6.  Did diabetes mellitus affect treatment outcome in drug-resistant tuberculosis patients in Pakistan from 2010 to 2014?

Authors:  A Latif; A Ghafoor; A Wali; R Fatima; Mahboob Ul-Haq; A Yaqoob; Z Abdullah; H Najmi; N M Khan
Journal:  Public Health Action       Date:  2018-03-21

7.  Treatment outcomes of multi drug resistant and rifampicin resistant Tuberculosis in Zimbabwe: A cohort analysis of patients initiated on treatment during 2010 to 2015.

Authors:  Ronnie Matambo; Kudakwashe C Takarinda; Pruthu Thekkur; Charles Sandy; Sungano Mharakurwa; Talent Makoni; Ronald Ncube; Kelvin Charambira; Christopher Zishiri; Mkhokheli Ngwenya; Saziso Nyathi; Albert Chiteka; Elliot Chikaka; Shungu Mutero-Munyati
Journal:  PLoS One       Date:  2020-04-30       Impact factor: 3.240

8.  Improving outcomes for multidrug-resistant tuberculosis: aggressive regimens prevent treatment failure and death.

Authors:  Gustavo E Velásquez; Mercedes C Becerra; Irina Y Gelmanova; Alexander D Pasechnikov; Askar Yedilbayev; Sonya S Shin; Yevgeny G Andreev; Galina Yanova; Sidney S Atwood; Carole D Mitnick; Molly F Franke; Michael L Rich; Salmaan Keshavjee
Journal:  Clin Infect Dis       Date:  2014-04-11       Impact factor: 9.079

9.  Validity of Time to Sputum Culture Conversion to Predict Cure in Patients with Multidrug-Resistant Tuberculosis: A Retrospective Single-Center Study.

Authors:  Arshad Javaid; Nafees Ahmad; Afsar Khan Afridi; Anila Basit; Amer Hayat Khan; Izaz Ahmad; Muhammad Atif
Journal:  Am J Trop Med Hyg       Date:  2018-03-29       Impact factor: 2.345

10.  Mortality in adults with multidrug-resistant tuberculosis and HIV by antiretroviral therapy and tuberculosis drug use: an individual patient data meta-analysis.

Authors:  Gregory P Bisson; Mayara Bastos; Jonathon R Campbell; Didi Bang; James C Brust; Petros Isaakidis; Christoph Lange; Dick Menzies; Giovanni B Migliori; Jean W Pape; Domingo Palmero; Parvaneh Baghaei; Payam Tabarsi; Piret Viiklepp; Stalz Vilbrun; Jonathan Walsh; Suzanne M Marks
Journal:  Lancet       Date:  2020-08-08       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.